ImmunityBio (IBRX) Operating Leases (2019 - 2026)
ImmunityBio (IBRX) posted quarterly Operating Leases of $40.8 million for Q1 2026, up 0.53% year-over-year from $40.6 million in Q1 2025, and up 21.9% quarter-over-quarter from $33.4 million in Q4 2025.
ImmunityBio (IBRX) Operating Leases (2019 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Operating Leases for 8 consecutive years, with $40.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases rose 0.53% year-over-year to $40.8 million; the TTM figure through Mar 2026 stood at $40.8 million (up 0.53% YoY), while the FY2025 annual figure was $33.4 million, down 3.95% from the prior year.
- Operating Leases climbed to $40.8 million in Q1 2026 per IBRX's latest filing, from $33.4 million in the prior quarter.
- Across five years, Operating Leases topped out at $52.1 million in Q2 2022 and bottomed at $33.4 million in Q4 2025.
- Historically, Operating Leases has averaged $42.0 million across 5 years, with a median of $40.6 million in 2025.
- Annual changes were most pronounced in 2022 — Operating Leases surged 140.17% — and 2023, when it declined 23.04%.
- ImmunityBio's Operating Leases stood at $48.0 million in 2022, then decreased by 16.7% to $39.9 million in 2023, then decreased by 12.82% to $34.8 million in 2024, then slipped by 3.95% to $33.4 million in 2025, then gained by 21.9% to $40.8 million in 2026.
- Business Quant data shows IBRX's Operating Leases at $40.8 million in Q1 2026, $33.4 million in Q4 2025, and $34.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38.71 Mn |
| Mar 31, 2026 | 40.77 Mn |
| Dec 31, 2025 | 33.45 Mn |
| Sep 30, 2025 | 34.13 Mn |
| Jun 30, 2025 | 35.84 Mn |
| Mar 31, 2025 | 40.56 Mn |
| Dec 31, 2024 | 34.82 Mn |
| Sep 30, 2024 | 36.76 Mn |
| Jun 30, 2024 | 42.70 Mn |
| Mar 31, 2024 | 44.32 Mn |
| Dec 31, 2023 | 39.94 Mn |
| Sep 30, 2023 | 39.31 Mn |
| Jun 30, 2023 | 50.54 Mn |
| Mar 31, 2023 | 49.26 Mn |
| Dec 31, 2022 | 47.95 Mn |
| Sep 30, 2022 | 51.09 Mn |
| Jun 30, 2022 | 52.05 Mn |
| Mar 31, 2022 | 39.76 Mn |
| Dec 31, 2021 | 37.07 Mn |
| Sep 30, 2021 | 37.71 Mn |